Universal Biosensors Inc (UBI) - Total Assets
Based on the latest financial reports, Universal Biosensors Inc (UBI) holds total assets worth AU$14.94 Million AUD (≈ $10.57 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Universal Biosensors Inc - Total Assets Trend (2002–2024)
This chart illustrates how Universal Biosensors Inc's total assets have evolved over time, based on quarterly financial data. Also see Universal Biosensors Inc market capitalisation for the company's overall valuation and market capitalisation.
Universal Biosensors Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Universal Biosensors Inc's total assets of AU$14.94 Million consist of 71.5% current assets and 28.5% non-current assets. Review UBI current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$8.54 Million | 33.1% |
| Accounts Receivable | AU$3.14 Million | 12.2% |
| Inventory | AU$5.59 Million | 21.6% |
| Property, Plant & Equipment | AU$6.95 Million | 26.9% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Universal Biosensors Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Universal Biosensors Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Universal Biosensors Inc's current assets represent 71.5% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 33.1% of total assets in 2024, up from 32.2% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is cash and equivalents at 33.1% of total assets.
Universal Biosensors Inc Competitors by Total Assets
Key competitors of Universal Biosensors Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
USA | $1.81 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Eurobio Scientific SA
PA:ALERS
|
France | €259.11 Million |
|
Profound Medical Corp
TO:PRN
|
Canada | CA$62.28 Million |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
Universal Biosensors Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 5.65 | 3.03 |
| Quick Ratio | 1.13 | 4.45 | 2.84 |
| Cash Ratio | 0.52 | 0.00 | 0.00 |
| Working Capital | AU$3.81 Million | AU$21.00 Million | AU$21.93 Million |
Universal Biosensors Inc - Advanced Valuation Insights
This section examines the relationship between Universal Biosensors Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.59 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -13.8% |
| Total Assets | AU$25.84 Million |
| Market Capitalization | $2.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Universal Biosensors Inc's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Universal Biosensors Inc's assets decreased by 13.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Universal Biosensors Inc (2002–2024)
The table below shows the annual total assets of Universal Biosensors Inc from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$25.84 Million ≈ $18.28 Million |
-13.79% |
| 2023-12-31 | AU$29.97 Million ≈ $21.21 Million |
-35.05% |
| 2022-12-31 | AU$46.15 Million ≈ $32.65 Million |
+3.69% |
| 2021-12-31 | AU$44.50 Million ≈ $31.49 Million |
-21.07% |
| 2020-12-31 | AU$56.38 Million ≈ $39.89 Million |
-10.02% |
| 2019-12-31 | AU$62.66 Million ≈ $44.34 Million |
-10.46% |
| 2018-12-31 | AU$69.98 Million ≈ $49.51 Million |
+51.26% |
| 2017-12-31 | AU$46.26 Million ≈ $32.73 Million |
-7.46% |
| 2016-12-31 | AU$49.99 Million ≈ $35.37 Million |
+11.21% |
| 2015-12-31 | AU$44.95 Million ≈ $31.81 Million |
-5.43% |
| 2014-12-31 | AU$47.53 Million ≈ $33.63 Million |
-12.98% |
| 2013-12-31 | AU$54.62 Million ≈ $38.65 Million |
+11.32% |
| 2012-12-31 | AU$49.07 Million ≈ $34.72 Million |
+8.52% |
| 2011-12-31 | AU$45.22 Million ≈ $31.99 Million |
-16.01% |
| 2010-12-31 | AU$53.84 Million ≈ $38.09 Million |
-4.00% |
| 2009-12-31 | AU$56.08 Million ≈ $39.68 Million |
+2.55% |
| 2008-12-31 | AU$54.69 Million ≈ $38.69 Million |
-14.36% |
| 2007-12-31 | AU$63.86 Million ≈ $45.18 Million |
+60.11% |
| 2006-12-31 | AU$39.88 Million ≈ $28.22 Million |
+823.84% |
| 2005-12-31 | AU$4.32 Million ≈ $3.05 Million |
+2.01% |
| 2004-12-31 | AU$4.23 Million ≈ $2.99 Million |
+1.39% |
| 2003-12-31 | AU$4.17 Million ≈ $2.95 Million |
+168.94% |
| 2002-12-31 | AU$1.55 Million ≈ $1.10 Million |
-- |
About Universal Biosensors Inc
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of… Read more